Q-omics provides the consensus-scored TRMT44 profile across patient tissues and cancer cell-line models. TRMT44 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, TRMT44 is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, TRMT44 RNA expression shows 20,718 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCEC, LIHC, and ACC as cancer lineages where TRMT44 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRMT44 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRMT44 survival associations across molecular data types. TRMT44 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRMT44 RNA expression–survival associations across cancer types. High TRMT44 expression shows unfavorable associations in LIHC, LGG, COAD and KICH, but favorable associations in UCEC and CHOL. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for TRMT44 RNA expression.
This table summarizes TRMT44 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 2. The strongest signals are observed in LIHC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TRMT44. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRMT44 shows lower tumor expression in BRCA, KICH and KIRP and higher tumor expression in LIHC, COAD and CHOL. The LIHC box plot shows higher TRMT44 RNA expression in tumor versus normal tissue (log2 FC = +0.701, t-test p < 0.001).
This table shows molecular features associated with TRMT44 in patient tissues and cancer cell lines. In patient samples, TRMT44 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRMT44 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
